Regulation 3
1. The following substances and products, namely—U.K.
Alprazolam
Aminorex
Bromazepam
Brotizolam
Camazepam
Chlordiazepoxide
[F11–(3–chlorophenyl)piperazine]
[F11–(3–chlorophenyl)–4–(3–chloropropyl)piperazine]
Clobazam
Clonazepam
Clorazepic acid
Clotiazepam
Cloxazolam
Delorazepam
Diazepam
Estazolam
Ethyl loflazepate
Fencamfamin
Fenproporex
Fludiazepam
Flurazepam
Halazepam
Haloxazolam
F2...
F3...
Ketazolam
Loprazolam
Lorazepam
Lormetazepam
Medazepam
Mefenorex
Mesocarb
F4...
Nimetazepam
Nitrazepam
Nordazepam
Oxazepam
Oxazolam
Pemoline
Pinazepam
Prazepam
Pyrovalerone
[F5Remimazolam]
Tetrazepam
Triazolam
N-Ethylamphetamine
[F6Zaleplon]
[F7Zolpidem]
[F8Zopiclone]
Textual Amendments
F1Words in Sch. 4 Pt. 1 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(3)
F2Words in Sch. 4 Pt. 1 para. 1 omitted (7.1.2015) by virtue of The Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/3277), regs. 1(1), 6
F3Word in Sch. 4 Pt. 1 para. 1 omitted (30.11.2015) by virtue of The Misuse of Drugs (Amendment) (No. 2) (England, Wales and Scotland) Regulations 2015 (S.I. 2015/891), regs. 1(3), 19
F4Word in Sch. 4 Pt. 1 para. 1 omitted (1.1.2008) by virtue of The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) Regulations 2007 (S.I. 2007/2154), regs. 2(3)(e), 4(13)
F5Word in Sch. 4 Pt. I para. 1 inserted (20.3.2024) by The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024 (S.I. 2024/248), regs. 1(2)(b), 2(4)
F6Word in Sch. 4 Pt. 1 para. 1 inserted (10.6.2014) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/1275), regs. 1(1), 6(a)
F7Word in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(b)
F8Word in Sch. 4 Pt. 1 para. 1 inserted (10.6.2014) by The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) (England, Wales and Scotland) Regulations 2014 (S.I. 2014/1275), regs. 1(1), 6(b)
2. Any stereoisomeric form of a substance specified in paragraph 1.U.K.
3. Any salt of a substance specified in paragraph 1 or 2.U.K.
4. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.U.K.
[F95. A liquid formulation—U.K.
(a)containing a botanical extract of cannabis—
(i)with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and
(ii)where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,
(b)which is dispensed through a metered dose pump as a mucosal mouth spray, and
(c)which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency on 16th June 2010]
Textual Amendments
Textual Amendments
F10Sch. 4 Pt. 2 heading substituted (23.4.2012) by The Misuse of Drugs (Amendment No.2) (England, Wales and Scotland) Regulations 2012 (S.I. 2012/973), regs. 1(1), 15
1. The following substances, namely—U.K.
[F115α–Androstane–3,17–diol]
[F11Androst-4-ene-3,17-diol]
[F111–Androstenediol]
[F111–Androstenedione]
[F124-Androstene-3, 17-dione]
[F135–Androstenedione]
[F125-Androstene-3, 17 diol]
Atamestane
Bolandiol
Bolasterone
Bolazine
Boldenone
[F14Boldione]
Bolenol
Bolmantalate
Calusterone
4-Chloromethandienone
Clostebol
[F15Danazol]
[F15Desoxymethyltestosterone]
[F16Dienedione (estra-4, 9-diene-3,17-dione)]
Drostanolone
Enestebol
Epitiostanol
Ethyloestrenol
Fluoxymesterone
Formebolone
Furazabol
[F17Gestrinone]
[F173–Hydroxy–5α–androstan–17–one]
Mebolazine
Mepitiostane
Mesabolone
Mestanolone
Mesterolone
Methandienone
Methandriol
Methenolone
Methyltestosterone
Metribolone
Mibolerone
Nandrolone
[F1819–Norandrostenedione]
[F1919-Nor-4-Androstene-3, 17-dione]
[F1919-Nor-5-Androstene-3, 17 diol]
[F2019–Norandrosterone]
Norboletone
Norclostebol
Norethandrolone
[F2119–Noretiocholanolone]
Ovandrotone
Oxabolone
Oxandrolone
Oxymesterone
Oxymetholone
Prasterone
Propetandrol
[F22Prostanozol]
Quinbolone
Roxibolone
Silandrone
Stanolone
Stanozolol
Stenbolone
Testosterone
[F23Tetrahydrogestrinone]
Thiomesterone
Trenbolone
Textual Amendments
F11Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(i)
F12Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(a)
F13Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(ii)
F14Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(iii)
F15Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(iv)
F16Word in Sch. 4 Pt. 2 para. 1 inserted (14.12.2016) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2016 (S.I. 2016/1125), regs. 1(1), 2(3)
F17Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(v)
F18Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(vi)
F19Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(b)
F20Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(vii)
F21Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(viii)
F22Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(ix)
F23Words in Sch. 4 Pt. 2 para. 1 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(a)(x)
2. Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -U.K.
(a)by further substitution at position 17 by a methyl or ethyl group;
(b)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
(c)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
(d)by fusion of ring A with a heterocyclic system.
3. Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.U.K.
4. The following substances, namely—U.K.
Chorionic Gonadotrophin (HCG)
Clenbuterol
Non-human chorionic gonadotrophin
Somatotropin
Somatrem
Somatropin
[F24Zeranol]
[F24Zilpaterol]
Textual Amendments
F24Words in Sch. 4 Pt. 2 para. 4 inserted (23.12.2009) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2009 (S.I. 2009/3136), regs. 1(1), 4(4)(b)
5. Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.U.K.
6. Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.U.K.
7. Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.U.K.